2. Academic Validation
  3. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

  • J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k.
Patrick R Verhoest 1,  Douglas S Chapin,  Michael Corman,  Kari Fonseca,  John F Harms,  Xinjun Hou,  Eric S Marr,  Frank S Menniti,  Frederick Nelson,  Rebecca O'Connor,  Jayvardhan Pandit,  Caroline Proulx-Lafrance,  Anne W Schmidt,  Christopher J Schmidt,  Judith A Suiciak,  Spiros Liras
Affiliations

Affiliation

  • 1 Neuroscience, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. [email protected]
PMID: 19630403 DOI: 10.1021/jm900521k
Abstract

By utilizing structure-based drug design (SBDD) knowledge, a novel class of phosphodiesterase (PDE) 10A inhibitors was identified. The structure-based drug design efforts identified a unique "selectivity pocket" for PDE10A inhibitors, and interactions within this pocket allowed the design of highly selective and potent PDE10A inhibitors. Further optimization of brain penetration and drug-like properties led to the discovery of 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920). This PDE10A inhibitor is the first reported clinical entry for this mechanism in the treatment of schizophrenia.

Figures
Products